Human VEGF-D Quantikine ELISA Kit

Product Details

Reactivity HuSpecies Glossary
Applications ELISA

Order Details

Human VEGF-D Quantikine ELISA Kit Summary

The Quantikine Human VEGF-D Immunoassay is a 4.5 hour solid phase ELISA designed to measure VEGF-D levels in cell culture supernates, serum, and plasma. It contains Sf 21-expressed, recombinant human VEGF-D and antibodies raised against the recombinant protein. Results obtained for naturally occurring human VEGF-D showed linear curves that were parallel to the standard curves obtain...ed using the kit standards. These results indicate that this kit can be used to determine relative mass values for natural human VEGF-D.
Show More
Natural and recombinant human VEGF-D
Assay Type
Solid Phase Sandwich ELISA
See PDF Datasheet for details
See PDF Datasheet for details
Spike Recovery
See PDF Datasheet for details
Sample Volume
See PDF Datasheet for details


Application Notes
No significant interference observed with available related molecules.
Read Publications using DVED00.

Packaging, Storage & Formulations

Store the unopened product at 2 - 8 °C. Do not use past expiration date.


This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Human VEGF-D Quantikine ELISA Kit

  • c-fos induced growth factor (vascular endothelial growth factor D)
  • FIGF
  • vascular endothelial growth factor D
  • VEGF-D
  • VEGF-DVEGFDc-Fos-induced growth factor


Vascular endothelial growth factor D (VEGF-D) is a homodimeric ligand of VEGF R3/Flt-4 and is synthesized with N- and C-terminal propeptides. Fully processed VEGF-D containing only the VEGF homology domain can additionally bind and activate VEGF R2/KDR/Flk-1. VEGF-D is expressed in adult lung, heart, muscle, and small intestine, and is most abundantly expressed in fetal lungs and skin. VEGF R3 is strongly expressed in lymphatic endothelial cells and is essential for regulation of the growth and differentiation of lymphatic endothelium. While VEGF-C is the critical ligand for VEGF R3 during embryonic lymphatic development, while VEGF-D is most active in neonatal lymphatic maturation and bone growth.

Customers Who Viewed This Item Also Viewed...

Species: Hu
Applications: ELISA
Species: Hu
Applications: ELISA
Species: Mu
Applications: CyTOF-ready, Flow, WB
Species: Mu
Applications: CyTOF-ready, Flow, IHC, Neut, WB
Species: Mu
Applications: IHC, WB
Species: Hu
Applications: Block, CyTOF-ready, Flow, IHC, WB
Species: Hu
Applications: ELISA
Species: Mu
Applications: IHC, WB
Species: Hu
Applications: WB
Species: Hu
Applications: ELISA
Species: Hu
Applications: BA
Species: Hu
Applications: BA
Species: Hu, Pm, Mu, Rt
Applications: ELISA, Flow, ICC/IF, IHC, IHC-P, WB
Species: Hu
Applications: ELISA
⚠ WARNING: This product can expose you to chemicals including N,N-Dimethylforamide, which is known to the State of California to cause cancer. For more information, go to

Publications for VEGF-D (DVED00)(35)

We have publications tested in 2 confirmed species: Human, Mouse.

Filter By Application
All Applications
Filter By Species
All Species
Showing Publications 1 - 10 of 35. Show All 35 Publications.
Publications using DVED00 Applications Species
L Fornaro, G Musettini, P Orlandi, I Pecora, C Vivaldi, M Banchi, F Salani, E Fini, V Massa, S Catanese, F Cucchiara, M Lencioni, G Masi, E Vasile, G Bocci Early increase of plasma soluble VEGFR-2 is associated with clinical benefit from second-line treatment of paclitaxel and ramucirumab in advanced gastric cancer American journal of cancer research, 2022;12(7):3347-3356. 2022 [PMID: 35968330] (Human) Human
I Wada, S Nakao, M Yamaguchi, Y Kaizu, M Arima, S Sawa, KH Sonoda Retinal VEGF-A Overexpression Is Not Sufficient to Induce Lymphangiogenesis Regardless of VEGF-C Upregulation and Lyve1+ Macrophage Infiltration Investigative Ophthalmology & Visual Science, 2021;62(13):17. 2021 [PMID: 34673901] (Human) Human
MA Wyatt, SC Baumgarten, AL Weaver, CC Van Oort, B Fedyshyn, R Ruano, CC Shenoy, EAL Enninga Evaluating Markers of Immune Tolerance and Angiogenesis in Maternal Blood for an Association with Risk of Pregnancy Loss Journal of Clinical Medicine, 2021;10(16):. 2021 [PMID: 34441875] (Human) Human
T Mashima, T Wakatsuki, N Kawata, MK Jang, A Nagamori, H Yoshida, K Nakamura, T Migita, H Seimiya, K Yamaguchi Neutralization of the induced VEGF-A potentiates the therapeutic effect of an anti-VEGFR2 antibody on gastric cancer in vivo Scientific Reports, 2021;11(1):15125. 2021 [PMID: 34302038] (Mouse) Mouse
H Wada, M Suzuki, M Matsuda, Y Ajiro, T Shinozaki, S Sakagami, K Yonezawa, M Shimizu, J Funada, T Takenaka, Y Morita, T Nakamura, K Fujimoto, H Matsubara, T Kato, T Unoki, D Takagi, K Wada, M Wada, M Iguchi, N Masunaga, M Ishii, H Yamakage, T Kusakabe, A Yasoda, A Shimatsu, K Kotani, N Satoh-Asah, M Abe, M Akao, K Hasegawa, Distinct Characteristics of VEGF-D and VEGF-C to Predict Mortality in Patients With Suspected or Known Coronary Artery Disease J Am Heart Assoc, 2020;9(9):e015761. 2020 [PMID: 32319336] (Human) Human
TH Chin, CP Lin, SD Chang, HS Wang, HY Huang, YK Soong, HM Wu, PH Chu Application of non-invasive detection of peripheral vascular dysfunction in ovarian hyperstimulation syndrome (OHSS): A pilot study of clinical relevance Taiwan J Obstet Gynecol, 2019;58(3):354-358. 2019 [PMID: 31122524] (Human) Human
M Hirose, A Matsumuro, T Arai, C Sugimoto, M Akira, M Kitaichi, LR Young, FX McCormack, Y Inoue Serum vascular endothelial growth factor-D as a diagnostic and therapeutic biomarker for lymphangioleiomyomatosis PLoS ONE, 2019;14(2):e0212776. 2019 [PMID: 30818375] (Human) Human
N Chebib, F Archer, A Bobet-Erny, C Leroux, V Cottin Dysregulation of the endothelin pathway in lymphangioleiomyomatosis with no direct effect on cell proliferation and migration Sci Rep, 2018;8(1):14698. 2018 [PMID: 30279475] (Human) Human
ECTD Nascimento, BG Baldi, AW Mariani, R Annoni, RA Kairalla, SP Pimenta, LFF da Silva, CRR Carvalho, M Dolhnikoff Immunohistological features related to functional impairment in lymphangioleiomyomatosis Respir. Res., 2018;19(1):83. 2018 [PMID: 29739412] (Human) Human
Kumar N, Moideen K, Sivakumar S, Menon P, Viswanathan V, Kornfeld H, Babu S Tuberculosis-diabetes co-morbidity is characterized by heightened systemic levels of circulating angiogenic factors. J Infect, 2017;74(1):10-21. 2017 [PMID: 27717783] (Human) Human
Show All 35 Publications.

Reviews for VEGF-D (DVED00) (0)

There are no reviews for VEGF-D (DVED00). By submitting a review you will receive an Amazon e-Gift Card or Novus Product Discount.
  • Review with no image -- $10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen
  • Review with an image -- $25/€18/£15/$25 CAD/¥150 Yuan/¥2500 Yen

Product General Protocols

Find general support by application which include: protocols, troubleshooting, illustrated assays, videos and webinars.

FAQs for VEGF-D (DVED00) (0)

There are no specific FAQs related to this product. Read our general customer & technical service FAQs.

Additional VEGF-D Products

Bioinformatics Tool for VEGF-D (DVED00)

Discover related pathways, diseases and genes to VEGF-D (DVED00). Need help? Read the Bioinformatics Tool Guide for instructions on using this tool.
Visit Tool

Diseases for VEGF-D (DVED00)

Discover more about diseases related to VEGF-D (DVED00).

Pathways for VEGF-D (DVED00)

View related products by pathway.

PTMs for VEGF-D (DVED00)

Learn more about PTMs related to VEGF-D (DVED00).

Blogs on VEGF-D

There are no specific blogs for VEGF-D, but you can read our latest blog posts.

Contact Information

Product PDFs

Review this Product

Be the first to review our Human VEGF-D Quantikine ELISA Kit and receive a gift card or discount.


Gene Symbol FIGF